Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) and Organovo (NASDAQ:ONVO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Valuation and Earnings
This table compares Lexeo Therapeutics and Organovo”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexeo Therapeutics | $650,000.00 | 404.35 | -$66.39 million | ($14.63) | -0.54 |
| Organovo | $110,000.00 | 55.75 | -$14.67 million | ($1.06) | -0.38 |
Organovo has lower revenue, but higher earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexeo Therapeutics | 0 | 0 | 8 | 1 | 3.11 |
| Organovo | 0 | 0 | 0 | 0 | 0.00 |
Lexeo Therapeutics currently has a consensus price target of $22.14, suggesting a potential upside of 178.53%. Given Lexeo Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than Organovo.
Insider and Institutional Ownership
60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 4.5% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 3.7% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Lexeo Therapeutics and Organovo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexeo Therapeutics | N/A | -103.43% | -51.50% |
| Organovo | N/A | -224.68% | -156.01% |
Summary
Lexeo Therapeutics beats Organovo on 10 of the 13 factors compared between the two stocks.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
About Organovo
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
